The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•24 February 2026•

1 min read

Corcept Therapeutics Faces Class Action Lawsuit After 50% Stock Plunge

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1A securities class action lawsuit has been filed against Corcept Therapeutics (CORT) and its top executives.

2The lawsuit alleges the company ignored repeated FDA warnings against filing a New Drug Application (NDA) for Relacorilant.

Corcept Therapeutics (CORT) and its top executives are facing a securities class action lawsuit following a massive 50% decline in the company's stock price. The litigation alleges that Corcept misled investors by ignoring repeated warnings from the FDA regarding its New Drug Application (NDA) for Relacorilant. According to the filing, the company failed to disclose significant "evidence gaps" in its clinical data, which eventually led to the sharp market sell-off. The lawsuit claims that management's actions caused substantial financial harm to shareholders who purchased the stock at artificially inflated prices. Investors have until April 21, 2026, to move for lead plaintiff status in the ongoing legal proceedings. This development adds significant regulatory and legal pressure to the biotechnology firm's outlook and market valuation.